high density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the field substudy高密度脂蛋白结构变化和药物反应lipidomic概要文件之后,substudy长期非诺贝特治疗领域.pdfVIP

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy 1 2. 1. 3,4 4 Laxman Yetukuri , Ilkka Huopaniemi , Artturi Koivuniemi , Marianna Maranghi , Anne Hiukka , Heli 1 2 4 5,6,7 8,9 Nygren , Samuel Kaski , Marja-Riitta Taskinen , Ilpo Vattulainen , Matti Jauhiainen , Matej ˇ ˇ 1,9* Oresic 1Technical Research Centre of Finland, Espoo, Finland, 2 Aalto University School of Science, Department of Information and Computer Science, Helsinki Institute for Information Technology, Espoo, Finland, 3 Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 4 Division of Cardiology, Department of Medicine, University of Helsinki, Helsinki, Finland, 5 Department of Physics, Tampere University of Technology, Tampere, Finland, 6 Department of Applied Physics, Aalto University School of Science and Technology, Espoo, Finland, 7 MEMPHYS – Center for Biomembrane Physics, University of Southern Denmark, Odense, Denmark, 8 National Institute for Health and Welfare, Helsinki, Finland, 9 Institute for Molecular Medicine Finland, Helsinki, Finland Abstract In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients assigned to fenofibrate therapy but the molecular mechanisms behind this are poorly understood. Herein we investigated HDL lipidomic